정규장
로그인 회원가입
ISRG
Intuitive Surgical Inc
7월 27일 9:35 AM ET (한국 7/27 22:35)
$337.47
+5.45 ▲ +1.64%

인튜이티브 서지컬(ISRG) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$119.2B
미드캡
P/E
38.7
적정 수준
배당수익률
없음
52주 위치
3%
저점 +3% · 고점 -44%
애널리스트
매수
B
Fundamental health
vs. Medical Instruments & Supplies
수익성
Top 15%
성장
Top 34%
밸류에이션
Top 29%
재무 안정
Top 49%
💰 Is this stock pricier than usual right now?
Compared to this company's own recent 5년 (not other companies).
💎 Very cheap
Cheap
Typical
Pricey
Very pricey
Simply put — what you pay today to own $1 of this company's yearly earnings is 38원. Over the past 5년, it usually traded around 71원. One of the cheapest stretches of the past 5년.
Pricy doesn't mean bad — it means expectations are already baked in.
Index NDX, S&P 500P/E 38.68EPS (ttm) 8.73Insider Own 0.67%Shs Outstand 353.9MPerf Week -2.3%
Market Cap 119.22BForward P/E 28.05EPS next Y 11.87%Insider Trans -2%Shs Float 350.9MPerf Month -16.02%
Enterprise Value 114.10BPEG 1.88EPS next Q 2.64Inst Own 85.73%Short Float 2.09%Perf Quarter -29.52%
Income 3.14BP/S 10.8EPS this Y 20.45%Inst Trans -0.16%Short Ratio 2.56Perf Half Y -35.82%
Sales 11.03BP/B 6.57EPS next 5Y 14.89%ROA 15.3%Short Interest 7.32MPerf YTD -40.41%
Book/sh 51.34P/C 22.72EPS past 3/5Y 29.18% 21.79%ROE 17.43%52W High -44.12% ($603.88)Perf Year -30.93%
Cash/sh 14.85P/FCF 37Sales past 3/5Y 17.39% 18.22%ROIC 17.28%52W Low 2.71% ($328.57)Perf 3Y 4.3%
Dividend Est. -EV/EBITDA 27.26EPS Y/Y TTM 21.06%Gross Margin 66.66%Volatility(W/M) 4.59% 3.59%Perf 5Y 3.68%
Dividend TTM -EV/Sales 10.34Sales Y/Y TTM 20.66%Oper. Margin 31.28%ATR (14) 15.85Perf 10Y 340.58%
Dividend Ex-Date -Quick Ratio 3.91EPS Q/Q 26.62%Profit Margin 28.45%RSI (14) 31.71Recom 1.77
Dividend Gr. 3/5Y -Current Ratio 4.96Sales Q/Q 18.54%SMA20 -13.1% ($388.34)Beta 1.48Target Price $497.93
Payout -Debt/Eq 0Earnings 2026/7/16SMA50 -17.1% ($407.08)Rel Volume 1.2Prev Close $332.02
Employees 17021LT Debt/Eq 0EPS/Sales Surpr. 11.5% 2.37%SMA200 -30.27% ($483.97)Avg Volume(3M) 2.86MPrice $337.47
IPO 2000/6/13Option/Short Yes/YesTrades 63915Volume 3,436,785Change 1.64%
Quarterly earnings trend SEC filings · USD
24.9
24.12*
25.3
25.6
25.9
25.12*
26.3
26.6
Revenue Net income 최근 분기: 매출 $2.9B (YoY +19%) · 순이익 $818M (YoY +24%)
* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Intuitive Surgical Inc (ISRG) Investment Analysis

What kind of company is Intuitive Surgical Inc?

인튜이티브 서지컬(ISRG) 성장주
Healthcare · Medical Instruments & Supplies
Top 134 by Market Cap — Large-Cap

Intuitive Surgical is a global leader in medical robotics, developing and supplying the da Vinci surgical robot system. Headquartered in Sunnyvale, California, USA, the company was founded in 1995 and has established itself as the global standard in minimally invasive robotic surgery. Its business model is characterized not only by system sales but also by recurring revenue from disposable instruments and services.

Learn more about Intuitive Surgical Inc →
Market Cap
$119B
Approx. KRW 163 trillion
⚖️ 41% of Samsung Electronics
Market Cap Rank134
Employees17,021people
IPO2000/06/13
Current Price$337.47 ≈ 462,334원
📌 NDX, S&P 500 · NASD · USA

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 7월 16일 (목) · 장 마감 후 EPS +11.5% 매출 +2.4%
🔔 Earnings release 2026년 4월 21일 (화) · 장 마감 후 EPS +17.8% 매출 +5.8%

Is it profitable?

Solid company — profitability & finances both healthy
Strong earnings and excellent financial health
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
31.3%
✓ 우수
My positionTop 5%
Low range Average High range
Medical Instruments & Supplies Median 5.5% · Top 2%
💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수
Net Margin
Share of revenue left after taxes and interest are paid
28.4%
✓ 우수
My positionTop 5%
Low range Average High range
Medical Instruments & Supplies Median -5.3% · Top tier
💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
66.7%
✓ 우수
My positionTop 25%
Low range Average High range
Medical Instruments & Supplies Median 48.6% · Top 15%
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROE
Annual return earned on shareholders' equity (15%+ is strong)
17.4%
✓ 양호
My positionMid-range
Low range Average High range
Healthcare 대형주 Median 11.9% · Top 37%
💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)
ROA
Annual earnings relative to total company assets
15.3%
✓ 우수
My positionTop 25%
Low range Average High range
Healthcare 대형주 Median 5.1% · Top 15%
💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수
ROIC
Return generated per dollar invested in the business
17.3%
✓ 우수
My positionTop 25%
Low range Average High range
Healthcare 대형주 Median 7.4% · Top 20%
💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.00
✓ Very low debt
My positionTop 5%
Low range Average High range
Medical Instruments & Supplies Median 0.26
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
4.96
✓ 우수
My positionTop 25%
Low range Average High range
Medical Instruments & Supplies Median 2.34
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
3.91
✓ 우수
My positionTop 25%
Low range Average High range
Medical Instruments & Supplies Median 1.97
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook
Price targets, growth, and valuation are favorable
애널리스트 목표가
$497.93
현재가 대비 +47.5%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
예상 PER (Forward)
28.05배
💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인
PEG (성장 반영 밸류)
1.88
다소 비쌈
💡 PEG 1.5~2 — 성장 대비 다소 비쌈
내년 EPS 예상 성장률
+11.9%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
+14.9%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Reliability
Beat estimates in 2 of the last 2 quarters
2
예상 상회
0
예상 부합
0
예상 하회
100%
상회 비율
+15.3%
평균 서프라이즈
2026.07.16
상회
실적 $2.80 · 예상 $2.50 +11.9%
2026.04.21
상회
실적 $2.50 · 예상 $2.11 +18.7%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth
Mid-range within the industry
Healthy, Balanced Growth EPS and revenue are both growing steadily — a sustainable growth profile
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+20.4%
양호
My positionMid-range
Low range Average High range
성장주 대형주 Median 15.4% · Top 37%
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+11.9%
평균
My positionMid-range
Low range Average High range
성장주 대형주 Median 13.1% · Bottom 39%
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
+14.9%
양호
My positionMid-range
Low range Average High range
성장주 대형주 Median 14.9% · Top 50%
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+29.2%
우수
My positionTop 25%
Low range Average High range
성장주 대형주 Median 9.2% · Top 17%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+21.8%
양호
My positionMid-range
Low range Average High range
성장주 대형주 Median 13.8% · Top 28%
Past 5-Year Revenue
How much revenue grew over the past 5 years
+18.2%
우수
My positionTop 25%
Low range Average High range
성장주 대형주 Median 10.3% · Top 19%
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
+18.5%
양호
My positionMid-range
Low range Average High range
성장주 대형주 Median 11.2% · Top 28%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Long-term weakness — -64%p below the market
ISRG +3.7% · S&P 500 +68.0%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-64.3%p
Significantly behind the market
vs Health Care (XLV)
-20.0%p
behind the sector average
1-year basis
vs S&P 500
-47.4%p
Significantly behind the market
vs Health Care (XLV)
-50.7%p
Significantly behind the sector average
Current position within 52-week range
Low (-2.7%p) High (-44.1%p)
Current price is 2.7% above the 52-week low and 44.1% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-34.5%
Annualized volatility
39.3%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴
Current diagnosis · 2026-07-24
Downtrend zone

Current price $337.47 below the midline ($388.32). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴
Current diagnosis · 2026-07-24
Bearish momentum holding

MACD -20.410 < Signal -13.801 in negative zone + Hist negative (-6.608). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴
Current diagnosis · 2026-07-24
Bearish zone

RSI 31.7 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 7.7.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

In line with the industry average
Pricey on Vs. Assets·Vs. Sales·Vs. Cash Flow, In line with peers on Vs. Earnings
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
💵 Vs. Earnings Mid-range
🏢 Vs. Assets Pricey
🧾 Vs. Sales Pricey
💧 Vs. Cash Flow Pricey
💵 Vs. Earnings
PER Price-to-Earnings Ratio
How expensive the price is vs. earnings — lower is cheaper
38.68x
✓ Fair
My positionMid-range
Low range Average High range
Medical Instruments & Supplies median 35.22x · Around the industry average
💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)
💵 Vs. Earnings
Forward PER Forward Price-to-Earnings Ratio
PER using next year's estimated earnings — reflects growth
28.05x
✓ Fair
My positionMid-range
Low range Average High range
Medical Instruments & Supplies median 18.44x · Around the industry average
💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
6.57x
✓ Pricey
My positionBottom 25%
Low range Average High range
Medical Instruments & Supplies median 2.71x · Bottom 17% — expensive within the industry
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
10.80x
✓ Pricey
My positionBottom 25%
Low range Average High range
Medical Instruments & Supplies median 2.92x · Bottom 25% — expensive within the industry
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
💧 Vs. Cash Flow
EV/EBITDA Enterprise Value Multiple
Total enterprise value ÷ operating cash earnings — a benchmark for M&A
27.26x
✓ Pricey
My positionBottom 25%
Low range Average High range
Medical Instruments & Supplies median 14.76x · Bottom 23% — expensive within the industry
💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)
💧 Vs. Cash Flow
P/FCF Price-to-Free-Cash-Flow Ratio
Price vs. actual cash generation — lower means more efficient
37.00x
✓ Fair
My positionMid-range
Low range Average High range
Medical Instruments & Supplies median 25.16x · Around the industry average
💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)
Analyst target price (reference)
$497.93 vs. current price +47.5%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Medical Instruments & Supplies

Who owns it?

Ownership flow shows some pressure
Insider modest net selling -2.0% · Institutional modest net selling -0.2% · Short interest light 2.1%
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
-2.0%
Insiders net selling
🏦 Institutions (funds & investors)
-0.2%
Institutions net selling
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 85.7%
Institution-led, stable structure
Healthcare 대형주 Median 91.9%
🧑‍💼 Insiders 0.7%
Low, common among large-caps
Healthcare 대형주 Median 0.8%
👤 Retail investors (estimated) 13.6%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
2.1%
Low — limited short-side pressure
Healthcare 대형주 Median 3.6%
Past 90 days Little change
Short interest days to cover
2.6 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 353.9M주
Float (tradable shares) 350.9M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding ISRG

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
ISRG This Stock
$119.2B38.7 6.6 17.43% - +1.6%
LLY
$1.13T43.0 36.2 107.64% 0.58% +0.9%
JNJ
$634.1B30.5 7.5 25.74% 2.04% +1.6%
ABBV
$458.2B127.9 - 15221.82% 2.65% +0.9%
UNH
$382.1B27.1 3.9 12.49% 2.15% -0.7%
MRK
$323.7B36.9 7.1 18.97% 2.49% +0.5%
Sector Avg-25.82.7-48.83%1.25%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

Derivative ETFs for ISRG

Leveraged, inverse, and covered call ETFs based on the underlying asset

1 derivative ETFs based on ISRG (Leverage 1)
These are based on the same underlying asset but carry a completely different risk and return profile. Please review the warning below first.
ℹ️ What is a Derivative ETF?
These are special ETFs that amplify, reverse, or monetize the price movement of an underlying ETF or security. Leveraged ETFs aim for 2–3× the daily move, Inverse ETFs target opposite-direction returns, and Covered Call ETFs generate monthly income from option premiums.
⚠️ Caution: Long-Term Holding
Leveraged and inverse ETFs track only the daily return. With high volatility, holding them for longer periods causes cumulative volatility decay—returns diverge further from the underlying index. They are meant for short-term trading.
📈 Leverage 1 ETFs that move 2-3x with ISRG (high volatility)
🧺
Deeper Analysis at the ETF Center ETF overlap, sector exposure, and X-Ray analysis tools

FAQ

What kind of company is 인튜이티브 서지컬(ISRG)?

인튜이티브 서지컬(ISRG) belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.

What is the market cap of ISRG?

The market cap of ISRG is approximately $119.2B, ranking 134 within its sector.

What is the P/E ratio of ISRG?

ISRG has a P/E ratio of approximately 38.7x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for ISRG?

ISRG has recorded a 52-week high of $603.88 and a low of $328.57.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.